COVID-19 Vaccine-Related Adverse Events in Solid Cancer Patients Treated with Immunotherapy.
Cancer Invest
; 40(9): 760-766, 2022 Oct.
Article
in English
| MEDLINE | ID: covidwho-2008390
ABSTRACT
Little data are available regarding the effects of COVID-19 vaccine in cancer patients undergoing immunotherapy. Thereby, COVID-19 vaccine-related adverse events were monitored through a short questionnaire in solid cancer patients receiving immunotherapy. A total of 95 patients were included in this study. Two doses of vaccines were administered to cancer patients which mainly received Pembrolizumab (51.1%). Respectively 78.2% and 62.2% of patients reported no adverse events after the first and the second dose regardless of the type of vaccine used. Considering the high mortality rate due to COVID-19 among cancer patients, this study demonstrated the good tolerance of COVID-19 vaccine.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
/
Neoplasms
Type of study:
Observational study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Cancer Invest
Year:
2022
Document Type:
Article
Affiliation country:
07357907.2022.2121966
Similar
MEDLINE
...
LILACS
LIS